Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction.

[1]  B. McConnell,et al.  Acute myocardial infarction in rats. , 2011, Journal of visualized experiments : JoVE.

[2]  J. Falck,et al.  Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury , 2011, British journal of pharmacology.

[3]  H. Krum,et al.  Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone , 2010, Clinical and experimental pharmacology & physiology.

[4]  David G. Behm,et al.  Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy , 2010, Peptides.

[5]  G. Gross,et al.  Review Article: Epoxyeicosatrienoic Acids: Novel Mediators of Cardioprotection , 2010, Journal of cardiovascular pharmacology and therapeutics.

[6]  H. Krum,et al.  Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats. , 2010, American journal of physiology. Heart and circulatory physiology.

[7]  H. Krum,et al.  Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? , 2010, European heart journal.

[8]  S. Hwang,et al.  Inhibition of Soluble Epoxide Hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid Is Protective Against Ischemia–Reperfusion Injury , 2010, Journal of cardiovascular pharmacology.

[9]  S. Hwang,et al.  Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches. , 2009, Journal of molecular and cellular cardiology.

[10]  U. Eriksson,et al.  Mechanisms of cardiac fibrosis in inflammatory heart disease. , 2009, Trends in cardiovascular medicine.

[11]  Paul D. Jones,et al.  Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy , 2009, Proceedings of the National Academy of Sciences.

[12]  Yuan Zhang,et al.  Perindopril attenuates tubular hypoxia and inflammation in an experimental model of diabetic nephropathy in transgenic Ren‐2 rats , 2008, Nephrology.

[13]  M. Lindsey,et al.  Macrophage roles following myocardial infarction. , 2008, International journal of cardiology.

[14]  J. Iliff,et al.  Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. , 2008, American journal of physiology. Heart and circulatory physiology.

[15]  J. Falck,et al.  Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. , 2008, American journal of physiology. Heart and circulatory physiology.

[16]  H. Krum,et al.  Long-Term but Not Short-Term p38 Mitogen-Activated Protein Kinase Inhibition Improves Cardiac Function and Reduces Cardiac Remodeling Post-Myocardial Infarction , 2008, Journal of Pharmacology and Experimental Therapeutics.

[17]  H. Krum,et al.  Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. , 2008, American journal of physiology. Heart and circulatory physiology.

[18]  A. A. Spector,et al.  Action of epoxyeicosatrienoic acids on cellular function. , 2007, American journal of physiology. Cell physiology.

[19]  C. Morisseau,et al.  Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble expoxide hydrolase , 2007, Cell Biochemistry and Biophysics.

[20]  B. Hammock,et al.  Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors , 2006, Proceedings of the National Academy of Sciences.

[21]  J. Falck,et al.  Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury. , 2006, American journal of physiology. Heart and circulatory physiology.

[22]  G. Torre-Amione.  Immune activation in chronic heart failure. , 2005, The American journal of cardiology.

[23]  P. Doevendans,et al.  Connective tissue growth factor expression and Smad signaling during mouse heart development and myocardial infarction , 2004, Developmental dynamics : an official publication of the American Association of Anatomists.

[24]  N. Khaper,et al.  Inflammatory cytokines and postmyocardial infarction remodeling. , 2004, Circulation research.

[25]  B. Hammock,et al.  Soluble Epoxide Hydrolase Inhibition Lowers Arterial Blood Pressure in Angiotensin II Hypertension , 2002, Hypertension.

[26]  B D Hammock,et al.  Soluble Epoxide Hydrolase Regulates Hydrolysis of Vasoactive Epoxyeicosatrienoic Acids , 2000, Circulation research.

[27]  R. Summers,et al.  Lidocaine and surgical modification reduces mortality in a rat model of cardiac failure induced by coronary artery ligation. , 2000, Journal of pharmacological and toxicological methods.

[28]  T. Matsumura,et al.  Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. , 1999, Journal of biochemistry.

[29]  D. Mann.  The effect of tumor necrosis factor-alpha on cardiac structure and function: a tale of two cytokines. , 1996, Journal of cardiac failure.

[30]  N. Reichek,et al.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[31]  P. Anversa,et al.  Myocardial Infarction in Rats: Infarct Size, Myocyte Hypertrophy, and Capillary Growth , 1986, Circulation research.

[32]  A. Bourthoumieux.  [Cardiac catheterization. 2]. , 1967, Revue de l'infirmiere et de l'assistante sociale.